Evidence map›Paper›PMID 38602539›Full record

Trial reportHuman vaccines & immunotherapeutics2024

Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial.

Tao Huang, Jun Yu, Siyuan Zhang, Dewei Teng, Defang Dai, Yinbiao Zhu, Lidong Gao

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Tao HuangDepartment of Vaccine Clinical Observation Center, Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, P.R. China.
Jun YuJiangsu GDK Biological Technology Co, Ltd, Taizhou, Jiangsu, P.R. China.
Siyuan ZhangDepartment of Vaccine Clinical Observation Center, Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, P.R. China.
Dewei TengDepartment of Vaccine Clinical Observation Center, Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, P.R. China.
Defang DaiDepartment of Vaccine Clinical Observation Center, Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, P.R. China.
Yinbiao ZhuJiangsu GDK Biological Technology Co, Ltd, Taizhou, Jiangsu, P.R. China.
Lidong GaoDepartment of Vaccine Clinical Observation Center, Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, P.R. China.
Hunan Provincial Center for Disease Control and Prevention · CNFrontier Environmental Technology (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immunogenicity and safety of the concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine (Split Virion) (QIIV) in Chinese adults are unclear. In this open-label, randomized controlled trial, participants aged ≥ 18 years were recruited. Eligible healthy adults were randomly assigned (1:1) to receive QIIV at the same time as the first dose of COVID-19 vaccine (simultaneous-group) or 14 days after the second dose of COVID-19 vaccine (non-simultaneous-group). The primary outcome was to compare the difference in immunogenicity of QIIV (H1N1, H3N2, Yamagata, and Victoria) between the two groups. A total of 299 participants were enrolled, 149 in the simultaneous-group and 150 in the non-simultaneous-group. There were no significant differences in geometric mean titer (GMT) [H1N1: 386.4 (95%CI: 299.2-499.0) vs. 497.4 (95%CI: 377.5-655.3); H3N2: 66.9 (95%CI: 56.1-79.8) vs. 81.4 (95%CI: 67.9-97.5); Yamagata: 95.6 (95%CI: 79.0-115.8) vs. 74.3 (95%CI: 58.6-94.0); and Victoria: 48.5 (95%CI: 37.6-62.6) vs. 65.8 (95%CI: 49.0-88.4)] and seroconversion rate (H1N1: 87.5% vs. 90.1%; H3N2: 58.1% vs. 62.0%; Yamagata: 75.0% vs. 64.5%; and Victoria: 55.1% vs. 62.8%) of QIIV antibodies between the simultaneous and non-simultaneous groups. For the seroprotection rate of QIIV antibodies, a higher seroprotection rate of Yamagata antibody was observed only in the simultaneous-group than in the non-simultaneous-group [86.0% vs. 76.0%,

Indexed as

COVID-19Influenza A Virus, H1N1 SubtypeInfluenza VaccinesAdultAntibodiesChinaCOVID-19 VaccinesHumansInfluenza A Virus, H3N2 SubtypeAntibodiesCOVID-19 VaccinesInfluenza Vaccinesconcomitant administrationimmunogenicityquadrivalent inactivated influenza vaccineRecombinant COVID-19 vaccinesafety

Identifiers

PMID38602539
PMCPMC11017946
OpenAlexW4394727327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.